Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gautschi

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
The Journal of Clinical Investigation|August 22, 2023
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancerFlorian Malchers, Lucia Nogova, Martijn Ha van Attekum, et al.
The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European PatientsSebastian Michels, Andreas Hans Scheel, Matthias Scheffler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR TrialSolange Peters, Sarah Danson, Baktiar Hasan, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryOliver Gautschi, Julie Milia, Thomas Filleron, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2016
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Rolf A Stahel, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|August 18, 2020
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patientsNir Peled, Roni Gillis, Saadettin Kilickap, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
The Journal of Clinical Investigation|August 22, 2023
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancerFlorian Malchers, Lucia Nogova, Martijn Ha van Attekum, et al.
The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European PatientsSebastian Michels, Andreas Hans Scheel, Matthias Scheffler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR TrialSolange Peters, Sarah Danson, Baktiar Hasan, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryOliver Gautschi, Julie Milia, Thomas Filleron, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2016
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Rolf A Stahel, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|August 18, 2020
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patientsNir Peled, Roni Gillis, Saadettin Kilickap, et al.
Pageof 10